Cohort demographics and pre-HSCT status
| Category . | Value . |
|---|---|
| Median age at HSCT, y | 14.0 (4.0-45.0) |
| Indication for HSCT | |
| Recurrent infection | 38 (92.7) |
| Lymphoma | 3 (7.3) |
| Chronic respiratory infection before HSCT | 38 (92.7) |
| Parenchymal lung disease at HSCT | 28 (68.3) |
| Bronchiectasis | 8 (19.5) |
| Pneumatocele | 13 (31.7) |
| Bronchiectasis and pneumatocele | 7 (17.1) |
| Median FEV1/FVC before HSCT, % predicted | 84.0 (28.0-122.0)/88.0 (26.0-115.0) |
| Pulmonary fungal infection before HSCT | |
| Confirmed | 13 (31.7) |
| Suspected | 2 (4.9) |
| Eczema before HSCT | 29 (70.7) |
| Category . | Value . |
|---|---|
| Median age at HSCT, y | 14.0 (4.0-45.0) |
| Indication for HSCT | |
| Recurrent infection | 38 (92.7) |
| Lymphoma | 3 (7.3) |
| Chronic respiratory infection before HSCT | 38 (92.7) |
| Parenchymal lung disease at HSCT | 28 (68.3) |
| Bronchiectasis | 8 (19.5) |
| Pneumatocele | 13 (31.7) |
| Bronchiectasis and pneumatocele | 7 (17.1) |
| Median FEV1/FVC before HSCT, % predicted | 84.0 (28.0-122.0)/88.0 (26.0-115.0) |
| Pulmonary fungal infection before HSCT | |
| Confirmed | 13 (31.7) |
| Suspected | 2 (4.9) |
| Eczema before HSCT | 29 (70.7) |
Data are presented as n (%) or median (range).
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.